Toloxatone

Summary

Toloxatone (CHEMBL18116) is an approved small molecule (ATC N06AG03); indicated across 1 condition including depressive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AG03
• Indications: 1 condition
• Chemistry: 207.23 Da · C11H13NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL18116
Name	Toloxatone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	34521
ChEBI	CHEBI:156575
ATC	N06AG03
Molecular formula	C11H13NO3
Molecular weight	207.23
InChIKey	MXUNKHLAEDCYJL-UHFFFAOYSA-N

SMILES: CC1=CC(=CC=C1)N2CC(OC2=O)CO

IUPAC name: 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one

ChEBI definition: A member of the class of oxazolidinones that is 5-(hydroxymethyl)-1,3-oxazolidin-2-one substituted by a 3-methylphenyl group at position 3.

Also known as: Humoryl, Toloxatona, Toloxatone, toloxatone, Taloxotone, TOLOXATONE, ToloxatoneÊ, ToloxatoneÂ

Patent coverage: 1,177 distinct patent families (4,955 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 4,952 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B, Amine oxidase [flavin-containing] B, Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] A.

Bioactivity

ChEMBL activities: 32 potent at pChembl ≥ 5 of 37 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P21398	6.42	Ki	380	nM	CHEMBL_ACT_1080255
P21396	6.42	Ki	380	nM	CHEMBL_ACT_1488571
P21398	6.42	IC50	380.2	nM	CHEMBL_ACT_1816334
P21398	6.42	IC50	380.2	nM	CHEMBL_ACT_2503562
P21398	6.42	Ki	380	nM	CHEMBL_ACT_8000758
MAOA	6.04	IC50	920	nM	CHEMBL_ACT_19104177
MAOA	6.03	IC50	930	nM	CHEMBL_ACT_19367833
MAOA	6.01	IC50	980	nM	CHEMBL_ACT_18304533
MAOA	5.97	IC50	1080	nM	CHEMBL_ACT_29197531
MAOA	5.97	IC50	1080	nM	CHEMBL_ACT_29220946
MAOA	5.96	IC50	1100	nM	CHEMBL_ACT_18494000
MAOA	5.83	AC50	1497	nM	CHEMBL_ACT_25159263
MAOA	5.82	Ki	1500	nM	CHEMBL_ACT_13338206
MAOA	5.79	IC50	1640	nM	CHEMBL_ACT_24869314
MAOA	5.79	IC50	1640	nM	CHEMBL_ACT_24965292
MAOA	5.75	IC50	1780	nM	CHEMBL_ACT_17987031
P21398	5.75	Ki	1800	nM	CHEMBL_ACT_2543852
MAOA	5.75	IC50	1770	nM	CHEMBL_ACT_29247267
MAOA	5.7	IC50	2000	nM	CHEMBL_ACT_18304563
P21396	5.49	IC50	3260	nM	CHEMBL_ACT_18197166
MAOA	5.41	IC50	3920	nM	CHEMBL_ACT_14710182
MAOA	5.41	IC50	3920	nM	CHEMBL_ACT_14753842
MAOA	5.41	IC50	3920	nM	CHEMBL_ACT_15161854
MAOA	5.41	IC50	3920	nM	CHEMBL_ACT_16380010
MAOA	5.41	IC50	3920	nM	CHEMBL_ACT_16472428
MAOA	5.41	IC50	3920	nM	CHEMBL_ACT_16562474
MAOA	5.41	IC50	3920	nM	CHEMBL_ACT_18249397
MAOA	5.41	IC50	3920	nM	CHEMBL_ACT_18811854
MAOA	5.41	IC50	3920	nM	CHEMBL_ACT_18858747
MAOA	5.41	IC50	3920	nM	CHEMBL_ACT_18876326

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
depressive disorder	4	MONDO:0002050	MONDO:0002009

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).